What is Sliding Scale Insulin?
Sliding scale insulin (SSI) is a reactive insulin regimen that administers short-acting or rapid-acting insulin based on current blood glucose measurements after hyperglycemia has already occurred, rather than proactively preventing it—and this approach is strongly discouraged by current clinical guidelines for most hospitalized patients. 1
Definition and Mechanism
Sliding scale insulin, also called correctional insulin, operates by:
- Using finger-stick blood glucose testing to assess current glucose levels
- Administering predetermined doses of rapid-acting or short-acting insulin based on these measurements
- Treating hyperglycemia after it has already developed rather than preventing it 1
This reactive approach fundamentally differs from physiologic insulin regimens that provide both basal (background) and prandial (mealtime) insulin coverage.
Clinical Evidence Against SSI Use
The evidence consistently demonstrates that SSI alone is inferior to basal-bolus regimens and is associated with poor outcomes:
- Glycemic control: SSI results in mean blood glucose levels 14.8 mg/dL (0.8 mmol/L) higher than basal-bolus regimens 2
- Hyperglycemic events: Significantly increased incidence compared to scheduled insulin regimens 3
- Clinical complications: Randomized trials show basal-bolus approaches reduce composite outcomes including postoperative wound infection, pneumonia, bacteremia, and acute renal and respiratory failure 1
The 2021 Lancet Diabetes & Endocrinology guideline explicitly states: "The use of sliding scale insulin is associated with clinically significant hyperglycemia in many patients and its use has been discouraged." 1
When SSI Might Be Appropriate (Limited Circumstances)
SSI may only be considered in highly specific situations:
- Patients without diabetes who have mild stress hyperglycemia 1
- Patients with well-controlled diabetes (HbA1c <7%) on minimal outpatient therapy 4
- Those with mild hyperglycemia and NPO status with no nutritional replacement 4
Critical caveat: SSI alone should never be used in patients with type 1 diabetes, as they require basal insulin to prevent diabetic ketoacidosis 1
Why SSI Persists Despite Evidence
Despite being condemned in clinical guidelines since at least 2012 (Beers Criteria) 5, SSI remains widely used because:
- It appears simple and requires less clinical decision-making
- It has been used for over 80 years, creating institutional inertia 6
- Healthcare providers may lack training in more appropriate insulin regimens
Recommended Alternative: Basal-Bolus Approach
Instead of SSI, guidelines recommend scheduled insulin regimens:
- Basal insulin: Long-acting insulin given once or twice daily (0.1-0.5 U/kg/day depending on patient factors)
- Prandial insulin: Rapid-acting insulin before meals
- Correctional insulin: Rapid-acting insulin for glucose excursions (used in addition to, not instead of, scheduled insulin) 1
This approach mimics physiologic insulin secretion and prevents hyperglycemia rather than chasing it after it occurs.
Key Clinical Pitfall
The most common error is using SSI as monotherapy in hospitalized patients with known diabetes. This reactive approach guarantees periods of hyperglycemia between measurements and fails to address basal insulin requirements, leading to worse clinical outcomes including increased infections, prolonged hospital stays, and higher mortality 6.